Fundamental Analysis of CBDMD INC(NYSEARCA:YCBD) stock

Fundamental Rating

YCBD gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 198 industry peers in the Pharmaceuticals industry. The financial health of YCBD is average, but there are quite some concerns on its profitability. While showing a medium growth rate, YCBD is valued expensive at the moment.

Quickly go to:

1. Profitability

1.1 Basic Checks

YCBD had negative earnings in the past year.

In the past year YCBD has reported a negative cash flow from operations.

YCBD had negative earnings in 4 of the past 5 years.

In the past 5 years YCBD always reported negative operating cash flow.

1.2 Ratios

The Return On Assets of YCBD (-158.87%) is worse than 89.23% of its industry peers.

YCBD has a Return On Equity of -340.82%. This is in the lower half of the industry: YCBD underperforms 78.97% of its industry peers.

		Industry Rank	Sector Rank
ROA	-158.87%
ROE	-340.82%
ROIC	N/A

ROA(3y)-122.9%

ROA(5y)-82.21%

ROE(3y)-186.47%

ROE(5y)-135.62%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

YCBD's Gross Margin of 63.88% is fine compared to the rest of the industry. YCBD outperforms 68.72% of its industry peers.

In the last couple of years the Gross Margin of YCBD has declined.

The Profit Margin and Operating Margin are not available for YCBD so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	63.88%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-0.51%

GM growth 5Y-4.55%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

YCBD does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, YCBD has more shares outstanding

YCBD has more shares outstanding than it did 5 years ago.

YCBD has a better debt/assets ratio than last year.

2.2 Solvency

YCBD has an Altman-Z score of -15.88. This is a bad value and indicates that YCBD is not financially healthy and even has some risk of bankruptcy.

YCBD's Altman-Z score of -15.88 is on the low side compared to the rest of the industry. YCBD is outperformed by 82.56% of its industry peers.

YCBD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-15.88

ROIC/WACCN/A

WACC9.02%

2.3 Liquidity

A Current Ratio of 1.23 indicates that YCBD should not have too much problems paying its short term obligations.

YCBD has a Current ratio of 1.23. This is amonst the worse of the industry: YCBD underperforms 82.56% of its industry peers.

A Quick Ratio of 0.64 indicates that YCBD may have some problems paying its short term obligations.

YCBD has a Quick ratio of 0.64. This is amonst the worse of the industry: YCBD underperforms 89.23% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	1.23
Quick Ratio	0.64

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 53.84% over the past year.

Looking at the last year, YCBD shows a very negative growth in Revenue. The Revenue has decreased by -27.12% in the last year.

The Revenue has been growing by 120.83% on average over the past years. This is a very strong growth!

EPS 1Y (TTM)53.84%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q-737.5%

Revenue 1Y (TTM)-27.12%

Revenue growth 3Y-16.76%

Revenue growth 5Y120.83%

Revenue growth Q2Q-11.73%

3.2 Future

The Earnings Per Share is expected to grow by 38.74% on average over the next years. This is a very strong growth

Based on estimates for the next years, YCBD will show a small growth in Revenue. The Revenue will grow by 4.85% on average per year.

EPS Next Y65.83%

EPS Next 2Y38.74%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year-8.39%

Revenue Next 2Y4.85%

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

YCBD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year YCBD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

YCBD's earnings are expected to grow with 38.74% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y38.74%

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

YCBD does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

CBDMD INC

NYSEARCA:YCBD (5/8/2024, 1:07:30 PM)

0.78

-0.02 (-2.5%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap2.38M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-158.87%
ROE	-340.82%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	63.88%
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover1.55

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	1.23
Quick Ratio	0.64
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)53.84%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y65.83%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-27.12%

Revenue growth 3Y-16.76%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

CBDMD INC (YCBD)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens